论文部分内容阅读
目的:探讨脊柱浆细胞瘤中基质金属蛋白酶-2(matrix metallopro teinase-2,MMP-2)和基质金属蛋白酶-9(MMP-9)蛋白的表达及其与脊柱浆细胞骨髓瘤生物学行为的关系。方法:应用免疫组织化学SP法检测41例脊柱浆细胞瘤及14例脊柱良性单纯性骨囊肿中MMP-2和MMP-9蛋白的表达。结果:41例脊柱浆细胞瘤中MMP-2和MMP-9蛋白阳性表达率(分别为63.41%和95.12%)明显高于良性骨囊肿(全阴性,P<0.01);MMP-2和MMP-9的过表达与患者生存期、临床分型、免疫球蛋白分型、轻链分型性别及年龄等比较均无统计学差异(P>0.05);但病理形态学分级与预后有相关性,病理分级为III级者平均生存期较I级和II级者明显降低。结论:病理形态学分级对浆细胞骨髓瘤的预后判断可能具有一定的临床意义;MMP-2和MMP-9在脊柱浆细胞瘤中的高表达也提示二者可作为新的抗转移治疗靶点。
Objective: To investigate the expression of matrix metallopro teinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in spinal plasmacytoma and their relationship with the biological behavior of spinal plasma cells relationship. Methods: Immunohistochemical SP method was used to detect the expression of MMP-2 and MMP-9 in 41 cases of spinal plasmacytoma and 14 cases of benign simple bone cysts. Results: The positive rate of MMP-2 and MMP-9 in 41 cases of spinal plasmacytoma was significantly higher than that of benign bone cyst (63.41% and 95.12% respectively) (all negative, P <0.01) There was no significant difference (P> 0.05) between the overexpression of 9 and the survival time, clinical classification, immunoglobulin typing, light chain genotyping and age (P> 0.05), but there was a correlation between pathological grade and prognosis The mean survival time of grade III patients was significantly lower than that of grade I and II patients. Conclusion: The pathological grading of myeloma prognosis may have some clinical significance; MMP-2 and MMP-9 high expression in spinal plasmacytoma also suggests that the two can be used as a new target of anti-metastasis .